GlobeNewswire Inc | Jan 6, 2022 07:00AM EST

January 06, 2022

MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022.

An on demand recording of the presentation will be available from January 10, 2022, at 07:00am ET in the News & Events section of ASLANs Investor Relations website at https://ir.aslanpharma.com/ and at the following link: https://journey.ct.events/view/849b8055-6a56-4b5b-a566-276449282256

Media and IR contacts

Emma Thompson Ashley R. RobinsonSpurwing Communications LifeSci Advisors, LLCTel: +65 6206 7350 Tel: +1 (617) 430-7577Email: ASLAN@spurwingcomms.com Email: arr@lifesciadvisors.com

About ASLAN PharmaceuticalsASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLANis currently evaluatingASLAN004, apotential first-in-classantibodytargeting the IL-13 receptor,in atopic dermatitis, and ASLAN003,apotent oralinhibitorofDHODH, which is being developed forautoimmune disease.ASLAN has a team in Menlo Park, California, and in Singapore.For additional information please visitwww.aslanpharma.comor followASLANon LinkedIn.